Search

Your search keyword '"Martín-Jiménez M"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Martín-Jiménez M" Remove constraint Author: "Martín-Jiménez M"
108 results on '"Martín-Jiménez M"'

Search Results

5. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)

10. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

11. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital

12. 1654P Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study

13. 1648P Association between circulating tumor cell count and thrombosis in pancreatic cancer

19. A new Iberian pleurosternid (Jurassic-Cretaceous transition, Spain) and first neuroanatomical study of this clade of stem turtles.

20. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788

21. 1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

22. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

23. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

24. LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

26. 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

27. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

28. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

30. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

34. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

38. Systematic study of the historical material of Upper Cretaceous reptiles from the Tremp Basin (Catalonia, Spain) housed at the Museo Nacional de Ciencias Naturales (Madrid)

39. Sistemas ultrasónicos para la irrigación del sistema de conductos radiculares

41. 323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)

44. 186P - Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms

45. 184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population

46. 148O - Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study

47. 162PD - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4)

49. Dental students' knowledge regarding the indications for antibiotics in the management of endodontic infections.

Catalog

Books, media, physical & digital resources